Drug Trial Radar · NCT06243640
Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD
Last checked: Nov 19, 2026Latest source record: Feb 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
504
Planned (sponsor's estimate)
Start
Jul 25, 2023
Primary completion
Jun 30, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Beijing Union Pharmaceutical Factory LtdIndustry
- Sponsor type
- Industry
- Collaborators
- R&G Pharma Studies Co.,Ltd.
- First posted
- Feb 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A placebo-controlled superiority design was used to evaluate the efficacy of 60 mg/ day or 120 mg/ day of Buagafuran capsules in the treatment of GAD
Conditions
- Generalized Anxiety Disorder
Interventions
Buagafuran capsules, 15mg/ capsuleDrug
Subjects took Buagafuran capsules; twice per day, respectively, after breakfast and dinner for 8 weeks;
Buagafuran capsules mimic, 0mg/ capsuleDrug
Subjects took Buagafuran capsules mimic. twice per day, respectively, after breakfast and dinner for 8 weeks;
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Hamilton anxiety scale score after treatmentTime frame: the end of week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Union Pharmaceutical Factory Ltd
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.